
iCell® Neurons are derived from human induced pluripotent stem (iPS) cells and provide a unique in vitro system for preclinical drug discovery, neurotoxicity testing, predictive disease modeling, and basic cellular research. A better and more biologically relevant alternative to current cell models, iCell Neurons offer researchers access to commercial quantities of high quality, highly pure human neurons that possess typical phenotypic characteristics and functional of mature neurons.
SpecificationsCellular Dynamics International’s iCell Neurons are a highly pure population of human neurons derived from induced pluripotent stem (iPS) cells using CDI’s proprietary differentiation and purification protocols. iCell Neurons are a mixture of post-mitotic neural subtypes, comprised primarily of GABAergic and glutamatergic neurons, with typical physiological characteristics and functions. These cells quickly assume a typical neuronal morphology with branching neurites. In addition, iCell Neurons display a stable adherent single-cell morphology and remain viable for an extended culture period (≥14 days), making them amenable to a variety of electrophysiology, neurotoxicity, and synaptic neurotransmission assays. Easy to implement and available in commercial quantities, these high quality, highly pure neurons are shipped as cryopreserved suspensions of dissociated cells with specifically formulated culture media. Once thawed, iCell Neurons remain viable for extended culture periods, allowing for acute and chronic studies.
iCell Neurons, Post-thaw, Represent a Highly Pure Population of Neurons and Extensive Neurite Networks |
|
Cell Type |
Neurons |
Catalog # |
NRC-100-010-001 (1 unit per vial) (Request a quote) |
Organism |
Human |
Source |
Differentiated from a CDI reprogrammed human iPS cell line |
Quantity |
>2.5 M platable cells per unit |
Shipped |
Frozen |
Storage |
Liquid nitrogen |
Growth Properties |
Adherent |
Media |
iCell Neurons Maintenance Medium, 100 ml
|
Human Cells |
iCell Neurons are terminally differentiated from human iPS cells that provide an easily accessible and biologically relevant model system to more accurately predict the relevant in vivo human response for preclinical drug discovery, neurotoxicity testing, predictive disease modeling, and basic cellular research.. |
Highly Pure Cell Population |
Provides neuron-specific responses to reference molecules. |
Homogenous and Reproducible |
iCell Neurons are available in sufficient homogenous quantities and demonstrate typical human neuron functions and responses, and are highly amenable for carrying out reproducible dose and time experiments. |
Fully Functional Model |
iCell Neurons exhibit standard biochemical characteristics of normal human neurons, and demonstrate utility in a variety of assays including electrophysiology, neurotoxicity, and synaptic neurotransmission assays. |
Easy to Implement |
Cells are shipped as cryopreserved suspensions of dissociated cells with iCell Neurons Maintenance Medium and iCell Neurons Medium Supplement, specially formulated for optimal cell performance. Simply thaw, mix and use. |
Acute and Longer-term Testing |
iCell Neurons remain viable in culture for at least 2 weeks, thus enabling assessment of both acute and longer-term testing. |
iPS Cell-derived |
iCell Neurons are differentiated from iPS cells reprogrammed from a non-embryonic terminally differentiated cell type, thus avoiding the controversial and ethical issues surrounding embryonic stem cell use. |
iCell Neurons perform well in a wide variety of including (but not limited to):
Cell-based Assays
Electrophysiological Applications
![]() |
Figure1: iCell Neurons Show a Cytotoxicity Dose Response to Known Compounds iCell Neurons were cultured for 7 - 14 days post-thaw and exposed to a dilution series of (A) staurosporine and (B) kainic acid. Viability (as measured using cellular ATP content) was determined using the CellTiter-Glo® Luminescent Cell Viability Assay. (Promega Corporation) |
![]() |
Figure 2: iCell Neurons Exhibit Neuron-like Action Potentials Evoked and spontaneous action potentials were recorded from an iCell Neuron (9 and 14 days, respectively) using a whole-cell patch clamp methodology. All action potentials demonstrate an overshoot of the depolarization phase above 0 mV and an undershoot of the repolarization phase below baseline before correction to steady-state. |
![]() |
Figure 3: iCell Neurons Respond to Ion Channel Blockers The conventional perforated patch voltage clamp technique was used with individual iCell Neurons to record the effects of compound application. The addition of classical neuron ion channel antagonists tetrodotoxin (TTX), tetraethylammonium (TEA) and nifedipine effectively blocked (A) inward sodium, (B) outward potassium, and (C) inward calcium currents, respectively, in iCell Neurons 12 - 13 days post-thaw. |
Request a quote or contact Cellular Dynamics:
+1 (608) 310-5100 | US toll-free +1 (877) 310-6688
In Japan, contact IPS Academia Japan:
+81 75 256-8582
|
Units per Vial |
Catalog # |
iCell Neurons* |
1 |
NRC-100-010-001 |
iCell Neurons Maintenance Medium |
|
NRM-100-121-001 |
iCell Neurons Medium Supplement |
|
NRM-100-031-001 |
* >2.5 M platable cells per unit |
||
Training |
Prior to storing, thawing, seeding, plating, and maintaining iCell Neurons, read the iCell Neurons User's Guide for proper handling techniques. In-lab training may be available upon request. |
Frequently Asked Questions |
See the list of FAQs here. |
Technical Support |
Call +1 (608) 310-5100 | US toll-free (877) 310-6688 or submit your technical question online. |
Reference Materials
User Documentation
Technology Overview
Datasheet |
iCell Neurons |
Application Notes |
Applying Transfection Technologies to Create Novel Screening Models
|
Presentations |
Induced Pluripotent Stem Cell-derived Tissues and their Role in Developing Novel Assays for Drug Discovery
|
|
Application of iPS Cell-derived Cells and a Novel Electrophysiology Platform for Neuronal and Cardiac Toxicity Evaluation and Drug Screening |
|
Advanced Assays for In Vitro Toxicity Evaluation and Phenotypic Screening |
|
Advancements in the Use of iPS Cell-derived Cells for In Vitro Disease Modeling and Phenotypic Screening |
|
Characterizing Human iPS Cell-derived Neuronal Cultures: Expression and Function of Ion Channels and Receptors |
|
Novel Assays for Drug Discovery and Toxicology Using Human iPS Cell-derived Neurons and Cardiomyocytes |
|
Bibliography |
Published Research |
Posters |
Application of Human iPS Cell-derived Models for Highly Predictive Toxicity Screening |
|
Development and Characterization of Human Induced Pluripotent Stem Cell-Derived Model Systems for |
|
|
Applications of Human iPSC-derived Neurons Using High-content Image-based Assays |
|
Development and Characterization of Human iPSC-derived Neurons for Drug Discovery Applications |
High Content Neuronal Toxicity Assays Using iPS Cell-derived Neurons |
|
Evaluation of Network Electrophysiology for Neurotoxicity Screening |
|
Optimization of Neuronal Cultures Derived from Human Induced Pluripotent Stem Cells for High Throughput Assays of Synaptic Function |
|
Applications Development at CDI: Improving Workflows, Pushing Biology, and Enabling Screening |
|
| Human iPSC-derived Cells for Modelling Cellular Bioenergetics: Building a Metabolic Profile Using the XF Mito Stress Test |
|
Advancements in the Use of iPS Cell-derived Systems for In Vitro Disease Modeling and Phenotypic Screening |
|
|
Implementation of Human iPSC-derived Cell Types Into High Throughput Screening Workflows |
|
User's Guide |
iCell Neurons
|
Application Protocols |
Assessing Neurite Outgrowth Using High Content Screening |
| Immunofluorescent Labeling |
|
|
Multielectrode Array System Application Protocol |
|
|
Plating into 1536-well Cell Culture Plates |
|
|
|
|
|
Performing Bioenergetic Analysis: |
|
Material Safety Data Sheets (MSDS) |
iCell Neurons |
iCell Neurons Maintenance Medium
|
|
|
iCell Neurons Medium
Supplement |
|
Datasheet |
Cellular Dynamics International: True Human Biology in a Dish |
Poster |
Reprogramming Human Peripheral Blood Cells |
Bibliography |
Published Research |